NASDAQ : MDXH

MDxHealth S.A.

$0.439 USD

$0.02 (5.76%)

Volume
474.39K
Average Volume
823.41K
Market Capitalization
$22.55M
P/E Ratio
-0.66
Dividend Yield
0.00%
Price Target
$4.00
Year High
$5.33
Year Low
$0.40
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.08
Source Headline
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.

globenewswire.com - 2026-07-02 16:00:00

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial

Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVINE, California – June 29, 2026– Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced the peer-reviewed publication of the Oxford GPS-ProMPT study in European Urology Oncology, one of the world's leading journals in genitourinary oncology. The publication represents the first major peer-reviewed milestone from the Oxford collaboration and serves as the foundation for evidence to be produced by the landmark GPS-ProtecT study.

globenewswire.com - 2026-06-29 08:00:00

MDxHealth Q1 Earnings Call Highlights

MDxHealth NASDAQ: MDXH reported first-quarter 2026 revenue of $27.4 million while announcing a strategic exit from its Resolve UTI testing business and the planned closure of its Plano, Texas, laboratory facility, a move executives said will sharpen the company's focus on prostate cancer diagnostics.

marketbeat.com - 2026-05-13 22:08:04

MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript

MDxHealth SA (MDXH) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 21:10:48

Mdxhealth Reports Q1-2026 Results

Mdxhealth Reports Q1-2026 Results Conference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, California – May 13, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2026. Michael K.

globenewswire.com - 2026-05-13 16:00:00

Mdxhealth to Release First Quarter 2026 Financial Results on May 13

Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended Mar

globenewswire.com - 2026-04-30 16:00:00

Get MDXH Insider Trade Alerts

MDXH Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$4.00

1 analysts

Last Year

$4.00

1 analysts

All Time

$9.50

2 analysts

MDXH Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-05-14 BTIG Maintain Buy Buy
2026-05-14 Lake Street Maintain Buy Buy
2026-05-14 TD Cowen Maintain Buy Buy
2025-12-23 BTIG Maintain Buy Buy
2025-11-13 Lake Street Maintain Buy Buy
2025-11-13 TD Cowen Maintain Buy Buy
2025-11-13 BTIG Maintain Buy Buy
2024-11-07 Piper Sandler Maintain Overweight Overweight
2024-03-07 BTIG Maintain Buy Buy
2024-03-07 Piper Sandler Maintain Overweight Overweight
2023-11-09 Piper Sandler Maintain Overweight Overweight
2023-06-20 BTIG Maintain Buy Buy
2023-05-31 TD Cowen Maintain Outperform Outperform
2023-05-15 BTIG Maintain Buy Buy
2023-04-19 BTIG Maintain Buy Buy
2023-03-24 William Blair Maintain Outperform Outperform
2023-03-08 BTIG Maintain Buy Buy
2023-03-05 Piper Sandler Maintain Overweight Overweight
2022-11-08 BTIG Maintain Buy Buy
2022-10-30 BTIG Maintain Buy Buy
2022-08-25 BTIG Maintain Buy Buy
2021-11-29 Piper Sandler Maintain Overweight Overweight
2021-11-29 BTIG Maintain Buy Buy
2021-11-29 Oppenheimer Maintain Outperform Outperform